"Health being a state subject, the primary responsibility of providing healthcare services is that of state governments.

The following is a summary of “Cutaneous manifestations of Fabry disease: A systematic review,” published in the March 2025 ...

Q4 2024 Earnings Call Transcript March 17, 2025 Sangamo Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Sangamo Therapeutics Inc (SGMO) reports significant progress in its Fabry disease program and neurology therapies, while ...

Reports Q4 revenue $7.6M, consensus $11.7M. “I am pleased with Sangamo’s (SGMO) pipeline progress since the start of 2024. We advanced our two ...

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results ...

Discover Protalix BioTherapeutics' Q4 2024 earnings insights, including record revenues, pipeline advancements, and future growth prospects.

Amicus Therapeutics benefits from strong revenue and limited competition. Learn why FOLD stock is a BUY, with a favorable ...

We recently compiled a list of the 12 Stocks Under $10 With High Upside Potential. In this article, we are going to take a look at where Amicus Therapeutics, Inc.

Background: Fabry disease (FD) is an X-chromosome-linked genetic disorder. Currently, the main treatments for FD include disease-nonspecific and disease-specific treatments. Nonspecific treatment ...

New immunotherapies have the potential to mediate a sustained remission from certain autoimmune diseases. This has been referred to as achieving an ‘immune reset’ in patients. Here ...

An upcoming event in Greenville is seeking to raise awareness and expand newborn screenings for a rare disease. WYFF 4 introduced you to Dr. Brian Jones and his wife, Tia, in February on an episode of ...